Production of lentiviral vectors by large‐scale transient transfection of suspension cultures and affinity chromatography purification
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The use of lentiviral vectors as gene delivery vehicles has become increasingly popular in recent years. The growing interest in these vectors has created a strong demand for large volumes of vector stocks, which entails the need for scaleable vector manufacturing procedures. In this work, we present a simple and robust process for the production of lentiviral vectors using scaleable production and purification methodologies. Lentivirus particles were produced by transient transfection of serum‐free suspension‐growing 293 EBNA‐1 cells with four plasmids encoding the vector components using linear polyethylenimine (PEI) as transfection reagent. This process was successfully scaled‐up from shake flaks to a 3‐L bioreactor from which 10 10 IVP were recovered. In addition, an affinity chromatography protocol designed for purification of bioactive oncoretroviral vectors has been adapted in this work for the purification of VSV‐G pseudotyped lentiviral vectors. Using heparin affinity chromatography, lentiviral particles were concentrated and purified directly from the clarified supernatants. During this step, a recovery of 53% of infective lentiviral particles was achieved while removing 94% of the impurities contained in the supernatant. Biotechnol. Bioeng. 2007; 98: 789–799. © 2007 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 6×
“…applications due to their Correspondence to: A. Kamen Contract grant sponsor: NSERC 2007 Wiley Periodicals, Inc. ability to integrate in the host cell genome, thereby providing the potential for long-term transgene expression in the transduced cells and their progeny (Naldini et al., 1996a,b).”
BackgroundMethodResultInfluentialA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 3×
“Additionally, it substantiates empirical findings by other research groups who also use higher relative amounts of transfer vector for transient transfection (Dull et al., 1998; Follenzi and Naldini 2002; Geraerts et al., 2005; Naldini et al., 1996b).”
BackgroundMethodResultNaldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 5×
“…applications due to their Correspondence to: A. Kamen Contract grant sponsor: NSERC 2007 Wiley Periodicals, Inc. ability to integrate in the host cell genome, thereby providing the potential for long-term transgene expression in the transduced cells and their progeny (Naldini et al., 1996a,b).”
BackgroundMethodResultInfluentialDevelopment of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · cited 3×
“The lentivirus vector plasmid used in this study is a self-inactivating (SIN) transfer vector (CSII-CMV5) containing the green fluorescent protein (GFP) reporter gene.”
MethodInfluentialLarge-Scale transfection of mammalian cells for the fast production of recombinant protein
Pham, P. L., Kamen, A., & Durocher, Y. (2006) · Molecular Biotechnology · doi:10.1385/mb:34:2:225 · Cited by 236 · cited 1×
“So far, the most widely used cell line in large-scale transient transfection protocols has been the 293E cells and the most widely used transfection reagent has been PEI (for review see Pham et al. (2006)).”
MethodSelf-citationBaekelandt, V, Eggermont, K., Michiels, M., Nuttin, B., & Debyser, Z. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302094 · Cited by 153
Rosser, M. P., Xia, W., Hartsell, S., McCaman, M., Zhu, Y., Wang, S., Harvey, S., Bringmann, P., & Cobb, R. R. (2005) · Protein Expression and Purification · doi:10.1016/j.pep.2004.07.015 · Cited by 68 · cited 2×
“However, it should be noted that in recent years transient transfection of suspension-growing cells has emerged as a powerful technology for the large-scale production of biopharmaceuticals (Durocher et al., 2002; Geisse and Henke 2005; Muller et al., 2005; Pham et al., 2003, 2005; Rosser et al., 2005; Sun et al., 200…”
Background
Cited by
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Progress and challenges in viral vector manufacturing
van der Loo, J. C. M., & Wright, J. F. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv451 · Cited by 255
Replication-competent Lentivirus Analysis of Clinical Grade Vector Products
Cornetta, K., Yao, J., Jasti, A., Koop, S., Douglas, M., Hsu, D., Couture, L. A., Hawkins, T., & Duffy, L. (2011) · Molecular Therapy · doi:10.1038/mt.2010.278 · Cited by 55
Lentiviral vectors for ocular gene therapy
Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081605 · Cited by 47
“LVs are mainly collected using a heparin column, but the elution is also dependent on salt concentration and requires an additional step such as a TFF for buffer exchange [58,69].”
Background
Metadata
- Authors
- Segura, M. M., Garnier, A., Durocher, Y., Coelho, H., & Kamen, A.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2007-04-26
- Volume
- 98
- Issue
- 4
- Pages
- 789-799
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2146299708
- Cited by
- 130
- References
- 7
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.